Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

NCT03636685 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Adenocarcinoma
Squamous Cell Carcinoma

Interventions

DRUG: Anlotinib combined with pemetrexed and carboplatin, phase I
DRUG: Anlotinib combined with paclitaxel and carboplatin, phase I
DRUG: Anlotinib combined with pemetrexed and carboplatin, phase II
DRUG: Anlotinib combined with paclitaxel and carboplatin, phase II

Sponsor

Chinese Academy of Medical Sciences